Daewoong Pharmaceutical signs Fexuprazan deal in Middle East



Daewoong Pharmaceutical signed a deal potentially worth 99.1 billion won ($83.7 million) with Aghrass Healthcare Limited to license its Fexuprazan gastroesophageal reflux treatment.
기사 더보기


대출디비

보험디비

카지노디비

디비판매


추천 기사 글